Company / Free Cash Flow
Amphstar Pharmaceuticals, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$121.2M
FY2025
5-year range
$65.1M / $172.3M
FY2021-FY2025
Trend
-29.7%
vs FY2024
Sector context
#44 of 194
Health Care
What the data says
Amphstar Pharmaceuticals, Inc.'s free cash flow of $121M is higher than 77% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 10 years, ranging from -$9M in FY2018 to $172M in FY2024.
Based on SEC 10-K filings.
$121M in FY2025 with a 5-year CAGR of +38.9%. Top quartile in the Health Care sector.
Declined from $145M to $121M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +23.0%
- 5-Year CAGR
- +38.9%
- 10-Year CAGR
- -
Sector benchmark
-74.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +38.9%, indicating consistent growth.
- In FY2025, free cash flow decreased 29.7% year-over-year.
- Ranks #44 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $121.2M | -29.7% |
| FY2024 | $172.3M | +18.6% |
| FY2023 | $145.3M | +123.1% |
| FY2022 | $65.1M | -7.6% |
| FY2021 | $70.5M | +201.3% |
| FY2020 | $23.4M | +11209.7% |
| FY2019 | $207.0K | +102.4% |
| FY2018 | -$8.6M | -309.7% |
| FY2017 | $4.1M | -76.1% |
| FY2016 | $17.2M | +423.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026